Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. - Wikidata - wikimedia - TriplyDB

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

http://www.wikidata.org/entity/Q33405246

about

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea Advances and challenges in the management of complement-mediated thrombotic microangiopathies Current Understanding of the Role of Complement in IgA Nephropathy Atypical hemolytic uremic syndrome: from diagnosis to treatment HUS and TTP in Children An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry Hemolytic uremic syndrome: toxins, vessels, and inflammation Complement regulator CD46: genetic variants and disease associations Complement System Part II: Role in Immunity Eculizumab: a review of its use in atypical haemolytic uraemic syndrome A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.Complement therapy in atypical haemolytic uraemic syndrome (aHUS).Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation.Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement.Macrovascular involvement in a child with atypical hemolytic uremic syndrome.Phenotypic expansion of DGKE-associated diseases [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient].Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report Neurodevelopmental long-term outcome in children after hemolytic uremic syndrome.Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation.Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies Remission of aHUS neurological damage with eculizumab Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome An international consensus approach to the management of atypical hemolytic uremic syndrome in children.The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.

P2860

Q24337607-35F11339-848E-4975-9C0C-266360313ACD Q26739894-1230AD58-99B6-4040-89DC-50CB4B904998 Q26796453-BFE24A22-3CEC-4EEA-A420-B3F4B6BB4065 Q26852163-C8975574-8287-495F-BC79-58E83709E8AC Q27023137-D79884FD-76BA-4058-94ED-52C4FF13F2D7 Q27026538-EE2C2FB6-AEDE-4BF3-AEBE-20F50FA0909D Q28068275-01FBBE33-D284-4698-AD56-491204F06640 Q28083347-A5CE0A22-6D4C-4E35-9B4F-FA0695F7B9E2 Q28263110-3EF66AA9-56B3-4E34-8815-8DBC552E7466 Q28263460-FAA27163-3335-4FFB-A250-188A96F0D04D Q28302228-070579F9-F1A3-4FA1-9D2F-3D53582DC098 Q28661698-B6A9DB95-2603-468E-A53B-F895B181CCD9 Q31010561-6F8883D3-39BE-4D5B-848C-C24D6E9FD199 Q33408733-C7782D39-A6CA-4A7D-B4A3-D124A1491FE6 Q33409540-0DC2CD6B-BDA2-4BB3-B1B3-B039F0F7CF2A Q33410871-7AD5F56A-3F70-4123-86D6-19A3B00C9685 Q33411956-CC72C8F9-B5A2-46EE-A616-29CA0DCD90BE Q33412191-9F2A0628-E9F8-41D7-84E4-BFD94DB81E44 Q33413254-5CCD916F-DD55-4088-90C9-AB196ACE2DA5 Q33413660-6699A244-FE30-4F11-8B53-0BEEDDA760CA Q33414109-24A21805-DC59-445E-A7BA-D92D09456889 Q33415218-56B3C824-2DB0-43F3-B8E9-994D1588007D Q33417375-F5BE0C9B-ED8B-45DA-9ECB-F8D8747E1D9E Q33417644-6315CC2C-ED5C-40AF-BCD1-E214B4F82040 Q33417655-1D71732E-D2A6-473E-A7DD-60289183E73F Q33417728-8BC952FB-C1E7-4E21-A1A4-63B4B24700F3 Q33418560-2AFF5654-803B-4305-9F1E-CB1321ED81C0 Q33418632-CC89DEBB-2022-418A-AC04-F449B723DFBC Q33418916-DB923AB8-3BAE-4771-BABB-9FD1A3E07B39 Q33419414-0756A105-FE6A-4BC7-B97C-A82EED51E57E Q33419812-BBE4DDC9-C157-4347-AB05-A896D919D5E7 Q33419905-42270D31-B2EC-4A28-A33D-950DD0711EE1 Q33420172-8051E347-A3C5-41ED-82E9-348F783FF5A4 Q33421493-E9D0A139-560A-4FE0-B378-3F2F0ABEA352 Q33421669-A6F1C121-F451-4CC5-8D36-7116356F8018 Q33421800-0E05A822-2ABD-4D60-836A-E718474F5E20 Q33421861-1475AAEF-287F-4D13-87AF-2E28D1244B13 Q33422057-C5F68167-DCDA-4A61-A34C-189FC007D24D Q33422224-5D55432B-FE8C-49A6-AD0D-E10A6742220D Q33422433-770FA37D-D015-482D-896C-AF178C9F6499

P2860

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

http://www.wikidata.org/entity/Q33405246

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Genetics and outcome of atypic ...... comparing children and adults.

@ast

Genetics and outcome of atypic ...... comparing children and adults.

@en

type

label

Genetics and outcome of atypic ...... comparing children and adults.

@ast

Genetics and outcome of atypic ...... comparing children and adults.

@en

prefLabel

Genetics and outcome of atypic ...... comparing children and adults.

@ast

Genetics and outcome of atypic ...... comparing children and adults.

@en

P1433

Q33405246-996375E7-2316-41FD-8ADB-D163541E12ED

P1476

Q33405246-6F3969E5-3D77-4F45-87C8-2BE946B965BE

P2093

Q33405246-24058DB2-7B7F-43F8-BFB1-7E04213F7708

Q33405246-3E19C5C6-AFC3-4A08-953C-EC820766499D

Q33405246-9E428449-8CDE-44FD-8111-3C1BC2276C7E

Q33405246-A7740FAA-650A-414F-A334-CA8FA173AF8A

Q33405246-AAF64E1B-3AA5-45A1-8C12-F4A5B50688B9

Q33405246-C7E54EDF-37AC-4FC6-A511-956C5B126F34

Q33405246-E0176077-1C7B-4519-8EEA-CB7732D23070

Q33405246-E0E85BED-DECB-4B5B-BE33-78B017BF275E

Q33405246-E3C11AE0-891C-42A6-9AD9-46E89316C1D2

P2860

Q33405246-1B642DB3-5B78-4249-BCE7-308E7642162C

Q33405246-352F78D6-1BE7-4092-89FD-0CFB6C3208D8

Q33405246-41C6051B-937A-441C-81B3-2E85F16B642D

Q33405246-7FCB28C7-7302-40A3-8B29-1D5F04CB98F5

Q33405246-869B8F5C-AB57-426D-B34B-E3A9B407350B

Q33405246-8BC32AF5-66D0-4E05-AD77-5C70B49CEDD0

Q33405246-91FF4CB3-B85A-4DA0-8DDA-A8BAA7E01084

Q33405246-933139BA-E825-48BB-B126-18F471CA8F79

Q33405246-99917D14-94EB-4042-8151-19E1328FF90B

Q33405246-9A94BE04-7051-40C7-8881-75427C63E4B2

P304

Q33405246-BB7298AF-9DE3-40E6-B424-2A504107F581

P31

Q33405246-5182A3CA-9999-4872-B828-22EBA369D32A

P356

Q33405246-78BBBDE9-CD57-46FE-9702-11D4A00DBD25

P433

Q33405246-1A8EFF12-933D-40A2-9321-3CCD7A858F1F

P478

Q33405246-C7775F68-2429-42B0-B549-2F438DFD5FA1

P50

Q33405246-171E41CA-9010-4C60-9A4F-C1815F0D6815

Q33405246-5DE4D65A-ECDA-4941-8C4F-24BC771C510D

Q33405246-7FF894CB-772A-4291-A02F-11C5DB8DA877

Q33405246-B4AA621F-2241-4083-B046-73E76AFEFD98

Q33405246-BCF1F8F2-3191-42FB-9AFA-FFD479158813

Q33405246-C9AF49FB-41AD-4580-BEBD-708A76CA28FC

Q33405246-D576E5FE-703F-4597-B9C2-C02E0B58B9C6

Q33405246-F686C7AA-D20B-4357-B910-E2B4C87ADF83

P577

Q33405246-9DE60DE1-A25E-47D8-87C7-DF21413671C2

P5875

Q33405246-61CBF661-F65E-4AC3-B6A4-13F50ABCF343

P698

Q33405246-80B81E4D-C76A-4BB0-B1F2-F4DD172F3989

P932

Q33405246-3C40196D-3F52-4C05-9532-7931DB32FE33

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Genetics and outcome of atypic ...... comparing children and adults.

@en

P2093

Arnaud Garnier

http://www.w3.org/2001/XMLSchema#string

Chantal Loirat

http://www.w3.org/2001/XMLSchema#string

Fadi Fakhouri

http://www.w3.org/2001/XMLSchema#string

François Provot

http://www.w3.org/2001/XMLSchema#string

Georges Deschênes

http://www.w3.org/2001/XMLSchema#string

Julien Zuber

http://www.w3.org/2001/XMLSchema#string

Patrick Niaudet

http://www.w3.org/2001/XMLSchema#string

Stéphanie Ngo

http://www.w3.org/2001/XMLSchema#string

Véronique Fremeaux-Bacchi

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.

Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree.

Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

P304

554-562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04760512

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Agnès Dragon-Durey

Georges Deschênes

Stephane Burtey

Frank Bienaimé

Lionel Rostaing

P577

2013-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234105922

http://www.w3.org/2001/XMLSchema#string

P698

23307876

http://www.w3.org/2001/XMLSchema#string

P932

3613948

http://www.w3.org/2001/XMLSchema#string